<?xml version='1.0' encoding='utf-8'?>
<document id="22112384"><sentence text="Use of a multistaged time-dependent inhibition assay to assess the impact of intestinal metabolism on drug-drug interaction potential." /><sentence text="In early discovery, compounds are often eliminated because of their potential to undergo metabolic activation and/or cytochrome P450 time-dependent inactivation (TDI)" /><sentence text=" The blockbuster drug raloxifene is an example of a compound that would have been eliminated in the current paradigm"><entity charOffset="22-32" id="DDI-PubMed.22112384.s3.e0" text="raloxifene" /></sentence><sentence text=" Despite raloxifene's in vitro bioactivation and TDI of CYP3A4, it is well tolerated in patients with no drug-drug interactions" /><sentence text=" This discordance is attributed to its presystemic glucuronidation, thereby decreasing the amount of unchanged raloxifene available for CYP3A inactivation"><entity charOffset="111-121" id="DDI-PubMed.22112384.s5.e0" text="raloxifene" /></sentence><sentence text=" The current study used raloxifene as a model to assess the effect of hepatic and intestinal glucuronidation on the kinetic parameters of CYP3A4 inactivation"><entity charOffset="24-34" id="DDI-PubMed.22112384.s6.e0" text="raloxifene" /></sentence><sentence text=" Therefore, a simple multistaged time-dependent inactivation using UDP-glucuronosyltransferase-enabled and -absent reactions was built to understand the impact of the gut metabolism on inactivation potential" /><sentence text=" The results of these experiments demonstrated a 2" /><sentence text="7-fold change in inactivation efficiency of CYP3A4" /><sentence text=" Incorporation of these results into a simulated midazolam drug-drug interaction study showed very little change in the pharmacokinetic parameters of the victim drug"><entity charOffset="49-58" id="DDI-PubMed.22112384.s10.e0" text="midazolam" /></sentence><sentence text=" In contrast, the absence of glucuronidation resulted in a 4" /><sentence text="1-fold increase in the area under the curve (AUC) of midazolam, when in the presence of raloxifene, hence providing an understanding of the impact of intestinal glucuronidation on raloxifene's time-dependent inhibition of CYP3A4 and also providing a validation of a simple in vitro experiment to assess the influence of gut metabolism on time-dependent inhibitors at the discovery phase"><entity charOffset="53-62" id="DDI-PubMed.22112384.s12.e0" text="midazolam" /><entity charOffset="88-98" id="DDI-PubMed.22112384.s12.e1" text="raloxifene" /><pair ddi="false" e1="DDI-PubMed.22112384.s12.e0" e2="DDI-PubMed.22112384.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22112384.s12.e0" e2="DDI-PubMed.22112384.s12.e1" /></sentence><sentence text="" /></document>